is allo-sct still relevant in the immuno-oncology era for hodgkin lymphoma?
Published 5 years ago • 179 plays • Length 5:27Download video MP4
Download video MP3
Similar videos
-
2:37
the current role and uncertain future of autosct in hodgkin lymphoma
-
1:00
efficacy of haploidentical sct for r/r classical hodgkin lymphoma
-
7:35
real-world analysis of hodgkin lymphoma outcomes after auto-sct
-
8:57
outcomes of sct in t-all and t-lbl
-
1:28
the role of autosct in hodgkin lymphoma
-
1:12
the evolving role of allosct in treatment of lymphoma
-
2:00
updates on treatment methods for hodgkin lymphoma
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
5:51
science talk with dr. jay l. wile, episode 06 | radioactive dating
-
4:10
how do natural killer cells target cancer?
-
21:38
drawing the line: the rationale behind blood tube collection order
-
1:03
late effect surveillance following allosct: the publication of new guidelines
-
1:21
the role of transplant in the era of new treatments for lymphoma and cll
-
0:54
the role of cd4 t-cells in the pathogenesis of hodgkin lymphoma
-
1:15
biomarkers being explored in hodgkin lymphoma: the role of ctdna
-
2:42
the current role of chemotherapy in the treatment of hodgkin lymphoma & the impact of novel agents
-
1:43
the addition of immunotherapy to the front-line treatment of as hodgkin lymphoma
-
2:11
the t-cell lymphoma project: prospective data collection changing the world
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:07
an insight into the pathogenesis of aml
-
1:21
novel approaches to harnessing the immune system in lymphoma